Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416644 | 1.00 | ALDH1A1 (0.42) | ALDH1A1ALOX5LMNATSHRCYP2C19 | |
| SCHEMBL24618229 | 0.91 | OPRM1 (0.45) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL31114026 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ALOX5LMNATSHRCYP2C19 | |
| SCHEMBL21431232 | 0.79 | ALDH1A1 (0.43) | ALDH1A1ALOX5LMNATSHRCYP2C19 | |
| SCHEMBL14239619 | 0.78 | TSHR (0.42) | TSHROPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL21392093 | 0.77 | CTPS1 (0.40) | ALDH1A1ALOX5NPSR1 | |
| SCHEMBL30725706 | 0.77 | CTPS1 (0.40) | ALDH1A1ALOX5NPSR1 | |
| SCHEMBL21410167 | 0.77 | ALOX5 (0.40) | ALDH1A1ALOX5LMNATSHRCYP2C19 | |
| SCHEMBL7807438 | 0.76 | ALDH1A1 (0.51) | ALDH1A1ALOX5LMNATSHRCYP2C19 | |
| SCHEMBL30633571 | 0.76 | RAB9A (0.36) | ALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-09-11 | — | — | US | disclosed |
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-07-29 | — | — | US | disclosed |
| US-20250066324-A1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2025-02-27 | — | — | US | disclosed |
| US-11987573-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2024-05-21 | — | — | US | disclosed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| CN-112839938-B | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| CN-112839938-A | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| EP-3768674-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2021-01-27 | — | — | EP | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | ALDH1A1 2030/4885ALOX5 4096/4885LMNA 4409/4885 |
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | ALDH1A1 1956/4885ALOX5 4177/4885LMNA 4396/4885 |
| US-20250066324-A1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | ALDH1A1 2030/4885ALOX5 4096/4885LMNA 4409/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | ALDH1A1 166/4885ALOX5 2571/4885LMNA 1782/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | ALDH1A1 166/4885ALOX5 2571/4885LMNA 1782/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | ALDH1A1 189/4885ALOX5 2430/4885LMNA 1780/4885 |
| US-11987573-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | ALDH1A1 2030/4885ALOX5 4096/4885LMNA 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.